Kronos Bio, Inc.
NASDAQ:KRON
Overview | Financials
Company Name | Kronos Bio, Inc. |
Symbol | KRON |
Currency | USD |
Price | 0.9 |
Market Cap | 54,265,140 |
Dividend Yield | 0% |
52-week-range | 0.69 - 1.6 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Norbert W. Bischofberger Ph.D. |
Website | https://kronosbio.com |
An error occurred while fetching data.
About Kronos Bio, Inc.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD